Stelios Papadopoulos is of Regulus Therapeutics Inc.. Currently has a direct ownership of 978,388 shares of RGLS, which is worth approximately $1.44 Million. The most recent transaction as insider was on Mar 14, 2024, when has been sold 250,000 shares (Common Stock) at a price of $1.6 per share, resulting in proceeds of $400,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 978K
0% 3M change
34.32% 12M change
Total Value Held $1.44 Million

STELIOS PAPADOPOULOS Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 14 2024
BUY
Grant, award, or other acquisition
$400,000 $1.6 p/Share
250,000 Added 20.35%
978,388 Common Stock
Apr 13 2023
BUY
Grant, award, or other acquisition
$199,978 $0.9 p/Share
222,198 Added 23.37%
728,388 Common Stock
Nov 30 2021
BUY
Grant, award, or other acquisition
$800,000 $0.36 p/Share
2,222,222 Added 30.51%
5,061,929 Common Stock
Dec 04 2020
BUY
Grant, award, or other acquisition
$499,923 $0.63 p/Share
793,528 Added 28.54%
1,986,729 Common Stock

Also insider at

EUCRW
Eucrates Biomedical Acquisition Corp.
EXEL
EXELIXIS, INC. Healthcare
BIIB
BIOGEN INC. Healthcare
SP

Stelios Papadopoulos

Alameda, CA

Track Institutional and Insider Activities on RGLS

Follow Regulus Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGLS shares.

Notify only if

Insider Trading

Get notified when an Regulus Therapeutics Inc. insider buys or sells RGLS shares.

Notify only if

News

Receive news related to Regulus Therapeutics Inc.

Track Activities on RGLS